Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 27, 2018

View Archived Issues

Dyanavel XR pharmacokinetics studied in younger pediatric population

Promising effects observed with JNJ-54175446 in major depressive disorder

UCM-924, a melatonin MT2 receptor agonist, shows promise for treating neuropathic pain

Portola Pharmaceuticals presents phase II data for cerdulatinib in patients with T-cell lymphoma

Cysteine protease ATG4B inhibitor LV-320 targets autophagy in leukemic cells

Researchers present new gene therapy for sickle cell anemia

Identification and evaluation of novel dual inhibitors of sodium-dependent glucose cotransporters

Otsuka opens enrollment in phase III trial of OPC-61815 for congestive heart failure

Momenta initiates phase II trial of M-281 in generalized myasthenia gravis

Alnylam Pharmaceuticals develops siRNA targeting the thrombopoietin gene in the liver

Novel CD38 CAR cell therapy for the treatment of multiple myeloma

Tumor-targeted trimeric 4-1BB-agonistic antibody 1D8N/CEGa1 shows safety and efficacy in vivo

ASO for LCA

New LAG-3 ligand identified

Oryzon patents lysine-specific demethylase inhibitors

NantBioScience reports high-affinity nerve growth factor receptor inhibitors

Shenzhen Salubris Pharmaceuticals describes DPP-IV inhibitors for diabetes

MEI Pharma initiates phase II study of ME-401 in follicular lymphoma

TRACON Pharmaceuticals submits IND application for TJ-4309

Mitophagy findings may offer new PD treatment promise

AbbVie licenses Lupin's MALT1 inhibitor program

Positive data presented from dose-escalation portion of phase I study of TRC-105

Sunshine Lake Pharma reports agents for the treatment of HBV infections

ROMK inhibitors reported in Bristol-Myers Squibb patent

Tyvyt approved in China for the treatment of Hodgkin's lymphoma

Capricor places voluntary hold on phase II HOPE-2 study of CAP-1002

FDA approves pediatric hexavalent combination vaccine Vaxelis

Arrowhead Pharmaceuticals initiates phase I study of ARO-ANG3

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...